1802929-43-6

Basic information

• Product Name: PRN-1371
• Synonyms: PRN-1371;8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one;8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one(WX135248)
• CAS NO: 1802929-43-6
• Molecular Formula: C26H30Cl2N6O4
• Molecular Weight: 561.4602
• EINECS: -0
• Mol File: 1802929-43-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PRN-1371(CAS DataBase Reference)
• NIST Chemistry Reference: PRN-1371(1802929-43-6)
• EPA Substance Registry System: PRN-1371(1802929-43-6)

Safety Data

• Hazardous Substances Data: 1802929-43-6(Hazardous Substances Data)

Usage

General Description

PRN-1371 is a novel, small molecule inhibitor of the SARS-CoV-2 main protease, which is an essential enzyme for the replication of the virus. It has been designed to specifically target this protease and inhibit its activity, thus potentially preventing the virus from replicating within infected cells. In preclinical studies, PRN-1371 has shown promising antiviral activity against SARS-CoV-2 and has demonstrated the potential to be an effective treatment for COVID-19. Its unique mechanism of action and potent inhibitory activity make it a valuable candidate for further development as a therapeutic intervention for coronavirus infections.

Upstream product

• 373608-48-1 4-(3-aminopropyl)piperazine-1-carboxylic acid tert-butyl ester 
• 148256-82-0 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxaldehyde 
• 1044145-59-6 [4-chloro-2-(methylsulfanyl)pyrimidin-5-yl]methanol 
• 857266-28-5 tert-butyl 4-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]piperazine-1-carboxylate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 132710-90-8 4-(3-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 153478-14-9 2,4-dichloro-1,5-dimethoxy-3-methylbenzene 
• 4179-19-5 1,3-dimethoxy-5-methylbenzene 
• 1384298-67-2 tert-butyl 4-(3-iodopropyl)piperazine-1-carboxylate 
• 5317-32-8 3-(1-piperazinyl)-1-propanol 
• 6512-32-9 methyl 2-(3,5-dimethoxyphenyl)acetate 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 

Relevant articles and documents

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our go

PROCESSES FOR PREPARING AN FGFR INHIBITOR

Disclosed herein are processes for preparing 8-(3-(4-acryloylpiperazin-l-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2- (methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and FGFR inhibitor, as well as polymorphs and/or salt forms thereof.